Despite adequately expressing tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors DR4/DR5, malignant cells are frequently refractory to the cytotoxic effect of this apoptosis-inducing ligand. The susceptibility of cancer cells to TRAIL can be potentiated by cisplatin (CDDP). This study was designed to evaluate the ability of cisplatin to enhance the cytotoxic effect of TRAIL gene therapy using the recombinant adenovirus-mediated tumor-selective expression of membrane-bound green fluorescence protein (GFP)-TRAIL fusion protein (AdVgTRAIL) on thoracic cancer cells and to elucidate the putative mechanisms responsible for this synergistic combination effect. While causing little death of cultured thoracic cancer cells by itself, AdVgTRAIL in combination with CDDP, on the other hand, mediated profound supra-additive cytotoxicity and apoptosis via a strong bystander effect. CDDP/AdVgTRAIL-induced cytotoxicity was completely abrogated either by the pancaspase inhibitor zVAD-fmk or by the selective caspase 9 inhibitor or by transient knockdown of caspase 9 by siRNA, indicating that this process was caspase-mediated and mitochondria-dependent. This was confirmed by the observation that Bcl2 overexpression protected the cells from combinationinduced cytotoxicity. Robust activation of caspase 8 activity in combination-treated cells was blocked by overexpression of Bcl2, indicating that caspase 8 activation was secondary to the mitochondria-mediated amplification feedback loop. Combining CDDP with AdVgTRAIL greatly enhances its tumoricidal efficacy in cultured thoracic cancer cells in vitro. The two agents interact to mediate profound activation of caspase cascade via recruitment of the mitochondria and positive feedback loop. The CDDP/ AdVgTRAIL combination also exhibits a strong antitumor effect in in vivo animal model of human cancer xenografts.
Introduction
Targeted cancer therapy aiming at direct induction of cell death by activation of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated signal-transduction pathways has attracted a great deal of attention and, in fact, recently entered early phase of clinical development. Recombinant protein (such as Apo2L/TRAIL 1 ) or recombinant human agonistic anti-DR4 or anti-DR5 monoclonal antibodies 2 are commonly used to activate TRAIL receptor for the induction of apoptosis of cancer cells. Binding of trimerized TRAIL to its functional receptors DR4 and/or DR5 results in receptor aggregation, recruitment of Fass-associated death domain, procaspases 8 (and 10) and other adaptor molecules to form the death-inducing signaling complex leading to activation of these initiator caspases. [3] [4] [5] [6] [7] [8] The death-inducing signaling complex-derived activated caspase 8 can then cleave and activate the executioner caspases 3 and 7 leading to apoptosis via a signaling cascade known as the extrinsic pathway, in contrast to the mitochondria-mediated intrinsic death signaling pathway activated following cytotoxic stresses. 9, 10 Moreover, activated caspase 8 can also process BID to yield truncated BID that translocates to the mitochondrial and, via interaction with Bak and Bax [11] [12] [13] on the mitochondria outer membrane, mediates the release of multiple proapoptotic proteins including cytochrome c, apoptosisinducing factor, second mitochondria-derived activation of caspases, thus linking the extrinsic to the intrinsic death signaling pathways. 9, 10, 14, 15 Cytochrome c, together with cytosolic apoptotic protease-activating factor-1, procaspase 9 and ATP, forms the apoptosome, which activates caspase 9 (serving as the initiator caspase for the intrinsic death pathway). Activated caspase 9 processes caspase 3 which in turn can proteolytically cleave and activate caspases 2, 8 and 10 through activated caspase 6 as an intermediary thus forming a positive amplification feedback loop to further activate the initiator caspase 8. [16] [17] [18] Death ligand-mediated induction of apoptosis is further classified into type I or II depending on the involvement of the intrinsic (mitochondria-mediated) death signaling cascade in the effective execution of apoptosis. Type I cells undergo death receptor-mediated apoptosis independent of mitochondria (and thus not sensitive to Bcl2/ BclXL), while type II cells rely on the intrinsic pathway for efficient apoptosis that is negated by Bcl2, BclXL or by the selective caspase 9 inhibitor Z-LEHD-fmk). 19 Despite expressing adequate levels of DR4/DR5 functional receptors for TRAIL, a significant proportion of cancer cells exhibit resistance to the cytotoxic effect of this ligand. [20] [21] [22] This can be overcome by combining Apo2L/TRAIL or anti-DR4 antibody with cytotoxic chemotherapeutics such as cisplatin or paclitaxel. 20, [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] While the underlying mechanisms responsible for the synergistic interactions between chemotherapeutics and TRAIL receptor agonists to mediate profound induction of apoptosis are complex, 5, 24, 25, [33] [34] [35] [36] it appears that recruitment/activation of the intrinsic death pathway (mitochondria-mediated) in combination-treated cells plays the crucial role.
Another strategy to activate TRAIL receptors is gene therapy using an adenoviral vector to introduce recombinant TRAIL gene into cancer cells to achieve high levels of this ligand within the tumor environment leading to robust tumoricidal activity via a paracrine effect. 37 Ingenious design of tissue-specific promoter system to selectively express therapeutic genes of interest in cancer cells using a recombinant adenoviral vector minimizes toxicity in normal cells while exploiting the potent tropism of adenovirus to eukaryotic cells. To this end, adenovirus expressing the membrane-bound green fluorescent protein (GFP)-TRAIL fusion protein under the control of the human telomerase reverse transcriptase (hTERT) promoter (AdVgTRAIL) has been constructed and shown to be selectively cytotoxic in transformed cells, but not normal cells, particularly human hepatocytes, as hTERT is overexpressed in up to 90% of cancer cells. [38] [39] [40] As a matter of fact, this construct has significant anticancer property with no apparent hepatotoxicity 40 when administered intravenously in animals bearing human xenografts and its tumoricidal activity is potentiated by combination with cytotoxic chemotherapy or ionizing radiation. [41] [42] [43] Moreover, the TRAIL gene therapy efficiently mediates apoptosis even in TRAILrefractory cells, 39, 44 making it an attractive alternative to recombinant TRAIL receptor ligands. Nguyen et al. 45 previously reported that pretreatment of cultured cancer cells with subtherapeutic concentrations of the chemotherapeutic drug cisplatin (CDDP) resulted in enhancement of adenoviral transgene expression (either the reporter gene b-galactosidase gene (LacZ) or the therapeutic gene p53 under the control of the cytomegalovirus (CMV) promoter/enhancer), via a yet to be defined mechanism. Moreover, CDDP has been shown to potentiate the cytotoxic effect of Apo2L/TRAIL in cultured cancer cells in vitro and in vivo. 20, 46 Thus, combining AdVgTRAIL with CDDP would exploit two potentially beneficial effects of this drug, namely the enhancement of adenoviral transgene expression in effector cells and the potentiation of a TRAIL effect on target cells within the same population of cancer cells infected with this virus. This study was designed to determine if CDDP enhances the therapeutic efficacy of adenovirus-mediated TRAIL gene therapy and at the same time elucidate the molecular mechanisms responsible for the synergistic cytotoxicity of this combination in cultured thoracic cancer cells.
Materials and methods
Cells and reagents. Cultured cancer cell lines H322, H460, H226 (non-small-cell lung cancer (NSCLC)), TE2, TE12, HCE4, SKGT5 (esophageal cancer (EsC)) and H513, H211, Gard (malignant pleural mesothelioma (MPM); Gard cells were generously provided by Dr HI Pass, NYU, New York, NY) were maintained in RPMI-1640 media supplemented with glutamine (2.0 mM), fetal calf serum (10% v/v) and antibiotics (streptomycin 100 mg ml À1 and penicillin 100 U ml À1 ). The tumor-selective AdVgTRAIL and AdV-hTERT-LacZ (a recombinant adenovirus expressing the galactosidase gene under the control of hTRERT promoter serving as vector control) and AdV-CMV-GFP viruses were obtained from the Keck Vector Center (University of Texas, MD Anderson Cancer Center, Houston, TX). The selective caspase 9 inhibitor z-LEDH-fmk and the general caspase inhibitor zVAD-fmk were purchased from R&D Systems (Minneapolis, MN). Bcl2-overexpressing stable transfectants of TE2 (TE2Bcl2), TE12 (TE12Bcl2) and H513 (H513Bcl2) cells were created by retrovirally mediated gene transfer using Bcl2-expressing viral vector (generously provided by P Robbins, Surgery Branch, NCI) and previously published transfection techniques. 47 Vector control stable transfectants of similar cancer cells were created using GFP-expressing retrovirus. The magnitude of GFP fluorescence in Bcl2 stable transfectants closely correlated with the level of Bcl2 expression. 47 Cells with the highest level of GFP were selected by cell sorting for further culture and expansion. This was followed by intracellular staining for Bcl2 using phycoerythrin (PE)-conjugated anti-Bcl2 monoclonal antibody (clone Bcl2/ 100, Alexis, San Diego, CA) after cell fixation and permeabilization using the Cytofix/Cytoperm kit from BD Biosciences (San Jose, CA Flow cytometry for GFP fluorescence. This technique provides an easy and quantitative method to determine the transfection efficiency (using AdV-CMV-GFP) and the magnitude of GFP-TRAIL fusion protein expression following AdVgTRAIL infection. Cells infected with AdVgTRAIL virus at MOIs of 5 or 10 PFU per cell with or without prior CDDP treatment in the presence of the pancaspase inhibitor zVAD-fmk (50 mM) were harvested 30 h after viral infection and subjected to flow cytometry for GFP fluorescence.
Cytotoxicity assays
Cell viability. Cells (1.5-1.75 Â 10 5 per well) were seeded in 12-well plates. After an overnight incubation, cells were treated with CDDP (0.5-4.0 mg ml À1 for 24 h) followed by AdVgTRAIL or AdV-hTERT-LacZ (at MOIs of 5 and 10 PFU per cell). Virus-containing media were removed after 24 h and replaced with 3.0 ml of fresh media for the rest of the assays. Cell viability was determined by 4,5-dimethylthiazo-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay 72 h after the onset of virus infection and expressed as percentages of untreated control cells. For two other treatment combinations, cells (seeded at 2.0 Â 10 5 per well) were either concurrently treated with CDDP and AdVgTRAIL for 24 h followed by replacement with fresh cultured media or sequentially treated with AdVgTRAIL ( Â 24 h) followed by CDDP ( Â 24 h).
Viability was then determined after 72 h of exposure to both components of the combination treatments.
Apoptosis. Cells were seeded in 12-well plates (1.5-1.75 Â 10 5 cells per well) and, after an overnight incubation, they were treated with CDDP (0.5-1.0 mg ml À1 for H513 cells, 1.0-2.0 mg ml À1 for TE12 cells and 2.0-4.0 mg ml À1 for H322 cells) for 24 h prior to exposure to AdVgTRAIL at 5 or 10 PFU per cell. AdVgTRAIL-or CDDP/AdVgTRAIL-treated cancer cells were incubated with 4 0 ,6-diamidine-2-phenylindole (1.0 mg ml À1 for 3 h) at 60 h after viral infection and examined with fluorescence microscopy. Apoptotic cells were identified as those with brightly blue fluorescent nuclei with condensed, fragmented DNA. Moreover, control and treated cells were harvested at 48 h after viral infection for quantitation of apoptosis using PE-conjugated Annexin V/7-AAD (BD Biosciences, Franklin Lakes, NJ) and flow cytometry.
Caspase activity. Cells were seeded in six-well plates at 5.0 Â 10 6 cells per well and subjected to AdVgTRAIL (5 or 10 PFU per cell) or CDDP (0.5 or 1.0 mg ml
À1
) followed by AdVgTRAIL treatments. Cells were then harvested at 2-h intervals starting at 14 h (H513) or 18 h (TE12) after AdVgTRAIL infection. Caspase 8, 9 and 3 activity of the cell lysates was measured using selective fluorescencetagged substrates (R&D Systems), normalized for the protein contents of cell lysates and expressed as fold of the activity of untreated control cells. À1 by intraperitoneal injections every 4 days for four times) or sequential intraperitoneal CDDP followed a day later by intratumoral AdVgTRAIL injection. Control tumorbearing animals were mock injected with phosphatebuffered saline. Tumor sizes were regularly measured until the animals were killed as per the following criteria: tumor volumes of 2000 mm 3 or development of surface ulceration or one of the orthogonal diameters reaching 2.0 cm. The animal experiment protocol as well as the conduct of the animal experiments was fully approved by the Animal Care and Use Committee of the National Institutes of Health. In vivo tumor selectivity of this AVdVgTRAIL virus was determined by examining GFP expression in tissue sections of tumor previously inoculated with this virus by fluorescence microscopy 24 h after virus inoculation (2 Â 10 8 PFU per injection in 50 ml injectate). Tumors or muscle samples frozen in OCT gel were cryostat sectioned and slides were counterstained with a mounting medium containing 4 0 ,6-diamidine-2-phenylindole stain (VECTASHIELD; Vector Laboratories, Burlingame, CA) and observed by fluorescence microscopy (Axioplan 2; Carl Zeiss MicroImaging, Thornwood, NY) at Â 40 magnification. Positive controls of GFP expression in both tumor and skeletal muscle samples were obtained using AdV-CMV-GFP virus. Treatment-induced apoptosis was determined by in situ TUNEL (terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling) staining using a commercially available kit (In Situ Cell Death Detection Kit; Roche Molecular Biochemicals, Indianapolis, IN). Briefly, samples were 10% formalin fixed and embedded in paraffin, sectioned, deparaffinized in serial xylene, rehydrated in graded alcohol and pretreated with proteinase K prior to TUNEL assay in accordance with the manufacturer's instructions. The slides were counterstained with fast red and representative images were captured at Â 40 magnification (Axioplan 2; Carl Zeiss MicroImaging).
Data analysis. Supra-additive therapeutic effects (cytotoxicity or apoptosis) are defined as effects induced by the drug combinations are, by statistical analysis, significantly greater than the algebraic sum of effects induced by individual drug treatments. Data are expressed as means±standard error of the means (s.e.m.) of at least three independent experiments that yielded similar results. Statistical analysis was performed with the GraphPad InStat software (GraphPad, San Diego, CA). Statistical analysis was performed using analysis of variance and pairwise comparison using Bonferroni test or by twotailed Student's t-test with Po0.05 indicating statistical significance.
Results
Increased cytotoxicity mediated by the CDDP and AdVgTRAIL combinations in cultured thoracic cancer cells The tumor-selective AdVgTRAIL at an MOI of either 5 or 10 PFU per cell caused a mild to moderate cytotoxicity in cultured thoracic cancer cells with only 10-40% reduction of cell viability in vitro ( Figure 1a ). All these cells express DR4 and DR5. They are susceptible to adenovirus-mediated gene transfer, as 60 to 490% of cells expressed GFP following AdV-CMV-GFP infection at MOIs of either 5 or 10 PFU per cell. There was no clear correlation between GFP fluorescence intensity and the percentage of GFP-positive cells following AdVgTRAIL infection and cytotoxicity of TRAIL gene therapy. As we have previously observed that CDDP enhances the susceptibility of cancer cells to recombinant soluble TRAIL, 20, 23 we next sought to define the cytotoxicity of CDDP and ADVgTRAIL combinations in our panel of cultured thoracic cancer cell lines. While either CDDP treatment alone or adenovirus TRAIL gene therapy alone mediated a mild reduction of cell viability, profound supra-additive cytotoxicity and apoptosis were observed in cells treated with the CDDP/AdVgTRAIL (CDDP followed by AdVgTRAIL) combination in a dosedependent manner (Figures 1b and 2a) . Moreover, comparable enhancement of cytotoxicity by the CDDP and adenovirus-mediated TRAIL gene therapy combinations was observed whether CDDP was administered before, during or after virus infection in all cell lines tested (H513, TE12, TE2, HCE4, H322 and SKGT5) (Figure 1c ; data not shown). This enhanced tumor-killing effect was 45 We next sought to determine if CDDP increased the expression of GFP-TRAIL gene under the control of the hTERT bicistronic promoter. By quantitating GFP fluorescence intensity using flow cytometry as a readout for GFP-TRAIL expression, we observed minimal (1.2-fold) to mild (1. ) or CDDP/AdVgTRAIL combination was determined by caspase activity assays at 2-h intervals starting at 14 h after AdVgTRAIL infection. Supra-additive elevation of caspase 8, 9 and 3 activities was observed in cells treated with the CDDP/ AdVgTRAIL combination as compared to caspase activity noted in cells treated with either CDDP alone or AdVgTRAIL alone (Figure 5a) . Elevation of caspase 9 activity following combination treatment indicates activation of the mitochondria-dependent (type II) death signaling cascade. Overexpression of Bcl2 or the caspase 9 inhibitor completely abrogated combination-induced activation of not only caspase 9 activation as expected but also of caspase 3 and most interestingly of caspase 8. A similar observation was made with TE2 and TE12 cells (Figure 5b ; data not shown). Blocking activation of the executive caspase 3 by Bcl2 overexpression or by the caspase 9 inhibitor indicated that this was entirely driven by the intrinsic pathway. Abrogation of caspase 8 activity by Bcl2 or caspase 9 inhibitor suggested that the type II mitochondria-dependent pathway downstream of caspase 8 mediated strong activation of this apical caspase in a retrograde manner via a positive feedback loop. The CDDP/AdVgTRAIL-mediated cytotoxicity was equally abrogated either by the pancaspase inhibitor zVAD-fmk or by the selective caspase 9 inhibitor, indicating that the mitochondria-dependent death signaling cascade plays an essential and exclusive role in this process (Figure 6a ). This notion was further confirmed by demonstrating that Bcl2 overexpression or caspase 9 knockdown by siRNA almost completely blocked the profound cytotoxic effect of the CDDP/AdVgTRAIL combination (Figures 6b and  c) . Ectopic overexpression of Bcl2 did not alter the levels of baseline DR4/DR5 expression (data not shown) nor the transduction efficiency of the adenovirus, as evidenced by comparable levels of TRAIL expression measured by TRAIL ELISA or flow cytometric analysis of TRAIL expression using PE-conjugated anti-TRAIL antibody (data not shown).
Enhancement tumoricidal activity of TRAIL gene therapy by CDDP Direct intratumoral injection of AdVgTRAIL resulted in slight but noticeable retardation of tumor growth (Figure 7a ). This was attributable to the anticancer effect of TRAIL, as no reduction of tumor growth was noted in tumors injected with AdV-hTERT-Lacz vector control. Without mediating any meaningful growth-inhibitory effect, CDDP interacted favorably with AdVgTRAIL to mediate a very strong tumoricidal effect that resulted in a 3.7-fold increase in survival compared to control animals and twofold increase in survival compared to the AdVgTRAIL-treated group (26 ± 2 days for control; 48±3 for AdVgTRAIL treatment and 96±7 days for the CDDP/ADVgTRAIL treatment, Po0.05 between control and AdVgTRAIL treatment, Po0.001 between control and combination treatment and between AdVgTRAIL alone and combination, by analysis of variance and Bonferroni pairwise comparisons). Similar to in vitro findings that AdVgTRAIL selectively expresses GFP-TRAIL in cancer and not normal cells (Figure 3) , examination of tumor or skeletal tissues infected with AdVgTRAIL virus by fluorescence microscopy revealed GFP-TRAIL expression only in tumor and not normal tissue samples (Figure 7b ), while GFP expression following AdV-CMV-GFP infection was equally observed in tumor and skeletal tissues. In situ TUNEL assay following CDDP, AdVgTRAIL or CDDP/AdVgTRAIL treatments indicated profound induction of apoptosis in tumors of combination-treated animals ( Figure 7c ).
Discussion
Direct induction of apoptosis of cancer cells by targeting death receptors using recombinant soluble TRAIL or agonistic anti-DR4 or anti-DR5 monoclonal antibody is an attractive therapeutic strategy because of its tumor selectivity and wide applicability in many cancers of different histology. TRAIL gene therapy using tumorselective adenoviral vector represents another clinically applicable strategy to directly induce apoptosis of cancer cells. Forced expression of membrane-bound TRAIL on target cancer cells using adenoviral vectors may achieve high local levels of this death-inducing ligand and thus potentially improve therapeutic efficacy. Owing to the nonspecific tropism of adenovirus for eukaryotic cells, especially those expressing the adenovirus receptor complex CAR and integrins aVb5/a5b3, cancer gene therapy using adenoviral vector expressing therapeutic genes driven by constitutively active promoter such as CMV has been limited to local or regional administration of viral vectors by either direct intratumoral injection or by selective infusion into hepatic artery to target liver metastasis. 49, 50 The applicability of TRAIL gene therapy is enhanced by the use of tumor-selective promoter system, such as the bicistronic hTERT promoter used to regulate TRAIL expression in our viral vector. The hTERT promoter is constitutively active in about 90% of cancer cells, while being silenced in normal cells Cisplatin sensitizes cancer cells to TRAIL gene therapy S Shamimi-Noori et al allowing selective expression of TRAIL in cancer and not normal cells. 39 This, in combination with the intrinsic resistance of normal cells to TRAIL, theoretically increases the safety of adenovirus-mediated TRAIL gene therapy. One potential disadvantage of this kind of promoter system is that therapeutic gene transcription is dependent on the activity of the hTERT promoter of the target cells and subtherapeutic expression of membranebound TRAIL may occur in cancer cells with weak hTERT promoter activity. Moreover, the hTERT promoter is about 10-fold less potent than constitutively active promoters such as CMV. 40 One, thus, trades promoter strength for tumor selectivity. Indeed, we observed that GFP expression was significantly less intense in cultured thoracic cancer cells infected with AdVgTRAIL than in those infected with similar viral 37, 48 Therapeutic levels of membrane-bound TRAIL can be achieved in vitro by increasing the MOIs but this may not be clinically achievable or even desirable especially in the setting of systemic delivery of the adenovirus, which is preferentially taken up by hepatocytes. This limitation can be overcome by sensitizing cancer cells to TRAIL using cytotoxic chemotherapeutic drugs or ionizing radiation. [41] [42] [43] We have previously observed that cultured thoracic cancer cells, while expressing adequate levels of DR4/ DR5, are generally refractory to the cytotoxic effect of the soluble recombinant death ligand Apo2L/TRAIL. [21] [22] [23] Infecting these cells with AdVgTRAIL caused at most moderate reduction of cell viability at an MOI of 10 PFU per cell. Higher cytotoxic effect could be achieved in some cell lines at higher MOIs of 20 or 50 PFU per cell (data not shown) but this might not be clinically practicable or achievable. These DR4/DR5-positive cells were adequately tranduced with AdVgTRAIL as evidenced by 440% cells expressing GFP, which may be sufficient for therapeutic efficacy based on a strong bystander effect as previously described for TRAIL gene therapy. Thus, levels of TRAIL receptors and adenovirus-mediated TRAIL expression are not limiting factors of this strategy of TRAIL gene therapy. In this study, we demonstrate that combining TRAIL gene therapy with sublethal concentrations of CDDP greatly enhances its cytotoxicity. Cisplatin has been previously reported to enhance adenovirus-mediated CMV promoter-driven gene expression in thoracic cancer cells. 45 Our initial attempts aiming at quantifying GFP-TRAIL fusion protein expression using flow cytometry indicated a minimal increase in the percentages of GFP-positive cells for H513 and H322 CDDP/AdVgTRAIL-treated cells versus AdVgTRAILtreated controls probably because these cells were quite permissible to adenovirus-mediated gene transduction. In the TE2 and TE12 cells, there was a more moderate (1.4-to 1.6-fold) increase in the percentages of GFP-positive cells following CDDP/ADVgTRAIL treatment. These were accompanied by a 1.5-(H322) to 3-fold (TE2, TE12) increase in the mean GFP fluorescence intensity. However, when ELISA was used to measure the level of TRAIL expression in cell lysates of H322, H513 and TE2 cells treated with CDDP alone, AdVgTRAIL alone (10 or 20 PFU per cell) or the CDDP followed by AdVgTRAIL combinations, one observed either a reduction (in H322 cells) to no change or a slight increase in TRAIL expression (in H513 or TE2 cells) in combination-treated cells. This was not likely to be attributable to loss of infected cells due to increased death and detachment from the monolayer as we did use zVAD-fmk to block treatment-induced apoptosis and harvested all adherent and nonadherent cells for the ELISA. We observed that CDDP-treated cells were larger than untreated controls and this may influence the fluorescence pattern of GFPpositive cells. The small but reproducible reduction of TRAIL expression in H322 cells treated with the CDDP followed by AdVgTRAIL combination may be the result of CDDP-mediated inhibition of intrinsic hTERT promoter activity as previous reports have indicated reduction of telomerase activity in CDDP-treated cells. 51, 52 Reduction of telomerase activity may reflect lower levels of telomerase, which could be due to either a reduction of gene transcription (lower promoter activity) or inhibition of transcript translation or increased degradation of the telomerase protein without alteration of gene transcription. Thus, in contrast to our previous observation 45 forming the basis of our initial hypothesis that CDDP may upregulate TRAIL transgene expression, we did not observe any significant increase of TRAIL in CDDPtreated cells compared to similarly infected untreated cells. As TRAIL expression is under the control of the hTERT promoter, one has to be careful in ascertaining that drug used in combination strategy to potentiate AdVgTRAIL cytotoxicity is not negatively affecting the intrinsic hTERT promoter activity of cancer cells. Indeed, ongoing experiments are being performed to investigate the effect of various chemotherapeutic agents, CDDP included, that may function as enhancers for TRAIL gene therapy on the intrinsic hTERT promoter activity of target cancer cells. The finding that enhanced cytotoxicity by the CDDP and AdVgTRAIL combinations can be achieved regardless of the order of CDDP administration relative to AdVgTRAIL infection would simplify the design of combination treatment and the choice of the sequence of drug exposure.
In contrast to our initial concerns that concurrently treating AdVgTRAIL-infected cells with CDDP could reduce the antitumor efficacy of the drug combination as CDDP may damage the viral genome or even suppress the host's hTERT promoter activity 51, 52 causing reduction of TRAIL expression, the AdVgTRAIL þ CDDP combination mediated profound cytotoxicity at levels comparable to those mediated by other two drug treatment schedules. It is very clear from our data demonstrating CDDP in combination with AdVgTRAIL (regardless of the treatment sequence schedule) mediated supra-additive cytotoxicity that the enhancement effect is likely due to CDDP globally sensitizing all CDDP-treated cells to TRAIL gene therapy and potentiating the bystander effect. We elected not to focus our effort on dissecting out the effect of CDDP on modulating the phenotypic expression of pro-and antiapoptotic proteins or members of the deathinducing signaling complex that play crucial roles in transducing death signals through the extrinsic and intrinsic pathways as previous works in our laboratory found this approach to be nonproductive. [21] [22] [23] We, instead, concentrated on functionally evaluating the role of the mitochondria-dependent intrinsic pathway and the positive caspase activation feedback loop on mediating the enhanced cytotoxicity observed in combinationtreated cells. The observation that profound cytotoxicity by the CDDP/AdVgTRAIL combinations was totally abrogated either by the selective caspase 9 inhibitor or siRNA-mediated knockdown of caspase 9 expression or by overexpression of Bcl2 provided irrefutable evidence that cell death in this setting was mediated exclusively by type II receptor-mediated apoptosis. More importantly, the strong caspase 8 activation in combination-treated cells was blocked by Bcl2 overexpression indicating the involvement of the intrinsic pathway in the amplification of caspase 8 (initiator caspase of the extrinsic pathway).
In summary, AdVgTRAIL in combination with CDDP mediates profound cytotoxicity and apoptosis of cultured thoracic cancer cells. Recruitment of the mitochondriamediated caspase activation cascade and the amplification feedback loop plays an essential functional role in this process. Cisplatin sensitizes the entire population of treated cells to TRAIL expression on a smaller fraction of successfully transduced cells leading to a more pronounced bystander effect. Malignant tumors of the esophagus are accessible by endoscopy, which provides a means for direct intratumoral injection of the adenoviral vector. Moreover, CDDP is frequently part of the firstline chemotherapy regimens for esophagheal cancers. The focus of our current investigation is therefore to further develop TRAIL gene therapy in combination with CDDP as potentially translatable novel targeted molecular therapy for esophageal cancers.
Abbreviations
AdVgTRAIL, replication-defective adenovirus expressing GFP-TRAIL gene under hTERT promoter; GFP, green fluorescence protein; TRAIL, tumor necrosis factorrelated apoptosis-inducing ligand; CMV, cytomegalovirus; LacZ, b-galactosidase gene; MTT, (4,5-dimethylthiazo-2-yl)-2, 5-diphenyl tetrazolium bromide.
